Plasma BDNF and PDGF-AA levels are associated with high TCD velocity and stroke in children with sickle cell anemia

Hyacinth, Hyacinth I.; Gee, Beatrice E.; Adamkiewicz, Thomas V.; Adams, Robert J.; Kutlar, Abdullah; Stiles, Jonathan K.; Hibbert, Jacqueline M.

doi:10.1016/j.cyto.2012.05.017

Cited by 35 publications

(31 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The majority of the candidate biomarkers in this study had been previously identified in studies of cerebral ischemia [24, 26-28], animal models of brain injury [24, 26, 28], vascular remodeling [27], and coagulation markers [22, 23], or showed previous associations with hemolysis [29], vaso-occlusive crises [30], abnormal TCD velocities [31] and stroke [30] in the SCD population. Proteomic discovery was used to find one candidate neuro-biomarker (glial fibrillary acidic protein [GFAP]) measured in two included studies, through testing of screening samples collected in the SIT study [24, 28].…”

Section: Description Of Studiesmentioning

confidence: 99%

“…Other studies used several different systems including Byk Sangtec Diagnostica, Behringwerke AG, Diagnostica stago, Diaclone SA, Roche Diagnostics, and Siemens Healthcare Diagnostics [22, 23]. Multiple analytes were assayed using the multiplex bead-based immunoassay systems by Biorad Bioplex [26, 27] and Millipore systems [27, 31]. Antibodies were also used in a flow-cytometry study to determine levels of platelet and erythrocyte microparticles [23].…”

Section: Description Of Studiesmentioning

confidence: 99%

“…IL-1β is a non-specific pro-inflammatory cytokine that is associated with microglia, astrocytes, and neurons. Data from one study showed that overall stroke risk was decreased with higher levels of IL-1β [26]; however, this finding was not replicated in a subsequent study by the same group in an expanded cohort [27]. Stroke risk was decreased with lower levels of BDNF, in addition to decreases in soluble vascular cell adhesion molecule-1 (s-VCAM-1), soluble intercellular adhesion molecule-1 (sICAM-1), PDGF-AA, and tissue plasminogen activator inhibitor (tPAI-1), which are involved in nerve growth, inflammation, endothelial activation, and thrombogenesis [31].…”

Section: Description Of Studiesmentioning

confidence: 99%

“…Stroke risk was decreased with lower levels of BDNF, in addition to decreases in soluble vascular cell adhesion molecule-1 (s-VCAM-1), soluble intercellular adhesion molecule-1 (sICAM-1), PDGF-AA, and tissue plasminogen activator inhibitor (tPAI-1), which are involved in nerve growth, inflammation, endothelial activation, and thrombogenesis [31]. A separate study showed that elevated levels of PDGF-AA correlated with stroke; however, association between the PDGF-AB/BB isoform and stroke was not found to be statistically significant [27]. Children with a history of stroke also had higher levels of fibrinopeptide A (FPA), TAT III, D-dimers, and serum platelet/endothelial cell adhesion molecule (PECAM-1) [22], as well as erythrocyte microparticles (ErMPs) and platelet-derived microparticles (PMPs) [23].…”

Section: Description Of Studiesmentioning

confidence: 99%

See 3 more Smart Citations

Proteomic and biomarker studies and neurological complications of pediatric sickle cell disease

Lance

Casella

Barron-Casella

2014

Proteomics Clinical Apps

View full text Add to dashboard Cite

Biomarker analysis and proteomic discovery in pediatric sickle cell disease has the potential to lead to important discoveries and improve care. The aim of this review article is to describe proteomic and biomarker articles involving neurological and developmental complications in this population. A systematic review was conducted to identify relevant research publications. Articles were selected for children under the age of 21 years with the most common subtypes of sickle cell disease. Included articles were focused on growth factors (platelet-derived growth factor), intra and extracellular brain proteins (glial fibrillary acidic protein, brain-derived neurotrophic factor), and inflammatory and coagulation markers (interleukin-1β, L-selectin, thrombospondin-1, erythrocyte and platelet-derived microparticles). Positive findings include increases in plasma brain-derived neurotrophic factor and platelet-derived growth factor with elevated transcranial Dopplers velocities, increases in platelet-derived growth factor isoform AA with overt stroke, and increases in glial fibrillary acidic protein with acute brain injury. These promising potential neuro-biomarkers provide insight into pathophysiologic processes and clinical events, but their clinical utility is yet to be established. Additional proteomics research is needed, including broad-based proteomic discovery of plasma constituents and blood cell proteins, as well as urine and cerebrospinal fluid components, before, during and after neurological and developmental complications.

show abstract

Section: Description Of Studiesmentioning

confidence: 99%

Section: Description Of Studiesmentioning

confidence: 99%

Section: Description Of Studiesmentioning

confidence: 99%

Section: Description Of Studiesmentioning

confidence: 99%

See 2 more Smart Citations

Proteomic and biomarker studies and neurological complications of pediatric sickle cell disease

Lance

Casella

Barron-Casella

2014

Proteomics Clinical Apps

View full text Add to dashboard Cite

show abstract

“…The authors wish to correct the numbers stated in the body and figures of the article titled 'Plasma BDNF and PDGF-AA levels are associated with high TCD velocity and stroke in children with sickle cell anemia', Epub June 15th 2012 and published October 1st 2012 in the Cytokine journal [1]. The values for plasma level of biomarkers quoted in the text and also the scales for the graphs/figures should be multiplied by 100 before use or quoting it.…”

mentioning

confidence: 97%